Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 67 O40 | DOI: 10.1530/endoabs.67.O40

EYES2019 7th ESE Young Endocrinologists and Scientists (EYES) Meeting Oral Presentations (67 abstracts)

T2-signal intensity, SST receptor expression and first-generation somatostatin analogs efficacy predict hormone and tumor responses to pasireotide in acromegaly

Eva C Coopmans 1 , Joppe J Schneiders 2 , Nour El-Sayed 1 , Nicole S Erler 3 , Leo J Hofland 1 , Patrick Petrossians 4 , Sjoerd van den Berg 5 , Aart-Jan van der Lely 1 , Ammar Muhammad 1 & Sebastian JCMM Neggers 1

1Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Department of Radiology, Erasmus University Medical Center, Rotterdam, The Netherlands; 3Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands; 4Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, Liège, Belgium; 5Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.

Objective: MRI T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigate the relationship between these predictors and the hormonal and tumor responses to PAS-LAR therapy, and compare to first-generation somatostatin receptor ligands (SRLs) responsiveness.

Methods: We included 45 acromegalics initially receiving SRLs, followed by a combination therapy including pegvisomant (PEGV), and finally PAS-LAR. Primary endpoints were tumor volume reduction (≥25% from baseline) and IGF-I levels (expressed as upper limit of normal (ULN)) during three months of PAS-LAR. We assessed T2-weighted MRI signal intensity by region of interest (ROI), visual assessment, SST receptor expression and IGF-I reduction (%) after SRLs.

Results: Significant tumor shrinkage was observed in patients with less IGF-I reduction during SRLs (mean 18.6% [S.D. 24.4] vs 35.1% [23.0], P=0.036), higher IGF-I levels during PAS-LAR (mean 1.36 [S.D. 0.53] vs 0.93 [0.43], P=0.020) and adenomas with low SST2 receptor expression (median 2.0 [IQR 1.0–6.0] vs 12.0 [7.5–12.0], P=0.040). Lower IGF-I levels during PAS-LAR were associated with higher T2-signal intensity (ß −0.29, 95% CI −0.56–−0.01). Patients with PAS-LAR-induced increased T2-signal intensity, achieved lower IGF-I levels (median 0.84 [IQR 0.51–1.28] vs 1.10 [0.82–1.30], P=0.047), while harboring relatively larger adenomas during PAS-LAR (median 1719 [IQR 1143–4616] vs 574 [170–2190], P=0.050).

Conclusions: Patients unresponsive to SRLs with low SST2 receptor expression are more prone to achieve tumor shrinkage during PAS-LAR. Surprisingly, tumor shrinkage is not accompanied by achieving lower IGF-I levels, which are associated with higher T2-signal intensity.

Volume 67

7th ESE Young Endocrinologists and Scientists (EYES) Meeting

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.